Monthly Archives: April 2022

Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Wednesday, May 4, 2022. In light of the coronavirus, the Annual General Meeting is conducted through advance voting pursuant to temporary regulations. Therefore, it will not be possible to attend this year’s Meeting in person or by proxy.

Read more here:
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics

Atreca Announces Licensing Agreement with Zymeworks

Read the original post:
Atreca Announces Expansion of Preclinical Pipeline

Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card

Read this article:
Athira Files Definitive Proxy Statement and Mails Letter to Shareholders

Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission

Read more:
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2022 financial results will be reported after the market closes on Tuesday, May 10th.

More:
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022

SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Eric Dobmeier, president and chief executive officer of Chinook Therapeutics, is scheduled to present and participate with management in 1x1 meetings at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 pm ET.

See the rest here:
Chinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced April conference presentations:

See the original post here:
IN8bio to Present at April Investor and Scientific Conferences

SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 4, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Go here to see the original:
Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, NuShield®, Novachor™ and Organogenesis Physician Solutions product lines will be showcased at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference held April 6-10, 2022 in Phoenix, Arizona.

Link:
Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring 2022 Conference

– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor –

Read more:
SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights